Skip to main content

Pharmacy news

Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information.

Two pharmacists check their inventory.

Exciting news!

Humana Pharmacy, soon becoming CenterWell Pharmacy

Effective June 11, 2022, we will introduce a new pharmacy brand to Humana members for the preferred cost-sharing pharmacy: Humana Pharmacy® will become CenterWell Pharmacy™. This brand change will also apply to Humana Specialty Pharmacy®, which will become CenterWell Specialty Pharmacy™.

All contact numbers will remain the same, both before and after the June 11 name change. But be aware, effective June 11, Humana Pharmacy and Humana Specialty Pharmacy will appear in your electronic medical record as:
Humana Pharmacy Mail Delivery (now CenterWell Pharmacy Mail Delivery): NCPDP ID # 0353108
Phone: 800-379-0092 (TTY: 711) | Fax: 800-379-7617
Humana Specialty Pharmacy (now CenterWell Specialty Pharmacy): NCPDP ID # 3677955
Phone: 800-486-2668 (TTY: 711) | Fax: 877-405-7940

Pharmacy news bulletins available on the portal

For a list of pharmacy news bulletins, pharmacists may sign in to the Pharmacist Portal. If you do not have access, you can register for a new account.

Additional notifications

Information about the launch of generic Flovent HFA

Effective May 28, 2022, generic Flovent HFA (fluticasone propionate) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Flovent HFA will continue to be covered and can be filled for patients.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Flovent HFA FAQs, PDF

Information about the launch of generic Breo Ellipta

Effective May 28, 2022, generic Breo Ellipta (fluticasone furoate/vilanterol) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans (excluding Value prescription drug plan). Brand-name Breo Ellipta will continue to be covered and can be filled for patients.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Breo Ellipta FAQs, PDF

Information about the launch of generic Dexilant

Effective April 1, 2022, generic Dexilant (dexlansoprazole) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Dexilant will continue to be covered and can be filled for patients.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Dexilant FAQs , PDF

Information about the launch of generic Restasis

Effective Feb. 12, 2022, generic Restasis (cyclosporine) is not covered or may require prior authorization on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Restasis will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Restasis FAQs , PDF

Information about the launch of generic Combigan

Effective Jan. 22, 2022, generic Combigan (brimonidine-timolol) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Combigan will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Combigan FAQs, PDF

Information about the use of ivermectin and COVID-19

The Centers for Disease Control and Prevention has released a health advisory regarding the rapid increase in ivermectin prescriptions and reports of severe illness associated with the use of products containing ivermectin to prevent and treat COVID-19.

Please see this notice, PDF for more information.

Information about the launch of generic Copaxone

Effective Jan. 1, 2022, generic Copaxone (glatiramer acetate) is not covered under Humana’s Basic and Walmart Value Part D plans. Brand-name Copaxone will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this medication may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Copaxone FAQs, PDF

Updates could mean new requirements for Humana members

Beginning Jan. 1, 2022, certain drugs will have new limitations or will require utilization management (e.g., prior authorization [PA] requirements, step therapy [ST] modifications and nonformulary [NF] changes) under the Humana commercial and Medicare formularies for the 2022 plan year.

These changes could mean higher costs or new requirements for Humana members who use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible. Depending on the member’s plan, Humana also may make positive and negative midyear changes for both commercial and Medicare formularies.

Information about the launch of generic Durezol

Effective Oct. 1, 2021, generic Durezol (difluprednate) is not covered by Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Durezol will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Durezol FAQs, PDF

Information about the launch of generic Mitigare

Effective Jan. 1, 2021, generic Mitigare (colchicine capsule) is not covered or may require step therapy on Humana’s Medicare Advantage prescription drug, Medicare Part D and commercial (including RxAdvantage) plans; brand Mitigare will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Mitigare FAQs, PDF

Information about the launch of generic Vascepa

Effective Nov. 7, 2020, generic Vascepa (icosapent) is not covered on Humana’s Medicare Advantage prescription drug and Part D plans; brand Vascepa will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Vascepa FAQs, PDF

Information about the launch of generic Tykerb

Effective Oct. 3, 2020, generic Tykerb (lapatinib) is not covered on Humana’s Medicare Advantage prescription drug and Part D plans; brand Tykerb will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Tykerb FAQs, PDF

Point-of-sale edits for hydroxychloroquine and chloroquine – effective 7/1/20, PDF opens in new window

Information about the launch of generic Symbicort HFA inhaler

Effective Jan. 11, 2020, generic Symbicort HFA inhaler (budesonide/formoterol HFA inhaler) is not covered or may require prior authorization for Medicare and commercial patients; brand Symbicort HFA inhaler will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Symbicort HFA inhaler FAQs, PDF

Information about the launch of authorized generic insulin aspart and insulin aspart mix

Effective Dec. 14, 2019, authorized generics for NovoLog and NovoLog Mix (insulin aspart and insulin aspart mix) came to market. They are currently under evaluation for Humana’s Medicare Advantage prescription drug plans, Medicare Part D plans and commercial plans; brand NovoLog and NovoLog Mix will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Authorized generic insulin aspart and insulin aspart mix FAQs, PDF

Information about the launch of generic Afinitor

Effective Dec. 14, 2019, generic Afinitor (everolimus) is not covered on Humana’s Medicare Advantage prescription drug and Part D plans; brand Afinitor will continue to be covered with prior authorization and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Afinitor FAQs, PDF

Med-Edit update notification

As of Jan. 1, 2018, Humana Pharmacy Solutions made enhancements to the opioid utilization program point-of-sale edits based on the opioid thresholds below. Please note: Patients with cancer or in hospice will not be flagged for this edit.

Med-Edit Notification, PDF